US/UK/Canada

Share

Quotes

Having studied the effects of radioisotopes on ovarian cancer, I believe that alpha-emitting radiopharmaceuticals represent a promising new approach for treating patients suffering from advanced ovarian cancer, who have been debulked to no residual tumor. All opportunities to improve the lives of ovarian cancer patients should be explored. Radspherin® has demonstrated compelling preclinical activity in multiple cancer models, and I am looking forward to further investigate it in this phase 1 study.
Professor Ignace Vergote, MD PhD FACS FSPS Chairman, Department of Obstetrics and Gynaecology Gynaecological Oncologist, University Hospital Leuven Belgium and lead clinical investigator
We are pleased that both phase 1 trials are now underway. This is a major milestone for the company. These studies are the first step in the clinical development of Radspherin®, and we expect them to provide important information about safety and distribution of the product candidate in the peritoneal cavity of patients suffering from peritoneal carcinomatosis. With the high unmet need in this underserved patient population and based on our encouraging preclinical data, we hope that Radspherin® may provide ovarian cancer and colorectal cancer patients with better outcomes. We are excited to have started the Phase 1 clinical program and we look forward to working closely with the hospitals and clinical researchers to advance the clinical development of Radspherin® as quickly as possible.
Jan A. Alfheim, Chief Executive Officer of Oncoinvent
Radspherin® represents a promising new approach for treating patients with metastates to the peritoneal cavity from colorectal cancer that may potentially provide a better outcome with longer progression free survival for patients that undergo cytoreductive surgery together with hypertherm intraperitoneal chemotherapy. We are always looking for opportunities to improve patient outcomes and give patients a better quality of life. Radspherin® has demonstrated preclinical activity in a range of cancer models, and we are excited to further investigate it in this Phase 1 study.
Stein Gunnar Larsen, M.D., Section Leader Department of Surgical Oncology, Oslo University Hospital, Norway
Radspherin® is a potentially transformative approach for a range of difficult-to-treat metastatic cancers. The mode of action of Radspherin® is to deliver a lethal dose of short range alpha radiation to remaining tumour cells in the peritoneum after surgery. Radium-224 emits alpha particles with high linear energy transfer (LET). There are no known cellular resistance mechanisms to this type of ionizing radiation, which may therefore be effective against dormant and chemo-resistant cancer cells remaining after surgical resection of macroscopic visible tumours and thereby increase the prospect of a complete response. We believe it could provide a profound benefit for patients that are in dire need of new therapies
Øyvind S. Bruland, M.D., Chief Medical Officer of Oncoinvent
“We are very excited to join forces with Oncoinvent,” said Ingrid Teigland Akay, Managing Partner with Hadean Ventures. “Oncoinvent holds world class expertise within radiopharmaceuticals and is now moving into clinical development with their lead compound to tackle conditions for which patients today have no good treatment options, including peritoneal carcinomatosis. We are looking forward to supporting Oncoinvent on this journey”
Dr. Ingrid Teigland Akay, Managing Partner with Hadean Ventures
“We are pleased to add Hadean Ventures to our list of shareholders,” said Oncoinvent Chief Executive Officer Jan A. Alfheim. “Having the financial support and industry expertise of Hadean Ventures will help us execute our vision even more rapidly and broadly. Furthermore, we are excited about the experience, perspective and relationships that a Nordics focused life science investor such as Dr. Teigland Akay can provide to our board of directors.”
Oncoinvent Chief Executive Officer Jan A. Alfheim
Oncoinvent Board Chair, Dr. Roy H. Larsen commented, “It is satisfying to note that after careful scrutiny of Oncoinvent via a thorough due diligence process, a professional life science fund manager such as Hadean Ventures has decided to make a significant investment in the company. I would like to welcome Dr. Teigland Akay to the Oncoinvent Board of Directors, and I look forward to working with her. “
Oncoinvent Board Chair, Dr. Roy H. Larsen
“We are pleased at the response that we have received from the investment community regarding our private placement. The round was heavily oversubscribed. With this financing round we now have, in addition to the new funding, a shareholder base in the company that will enable Oncoinvent to bring Radspherin™ to a clinical proof of concept.”
Jan A. Alfheim, Oncoinvent’s CEO
Pick a time period -
Tags ( Active)

Merger of BerGenBio and Oncoinvent completed

Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA ("Oncoinvent") through a statutory triangular merger (the "Merger"), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two companies. Reference is further made to the stock exchange announcement made on 24 October 2025 regarding key dates for completion of the Merger and the stock exchange announcement made on 28 October 2025 regarding the approval and

Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the presentation of the previously reported final 18-months safety and efficacy results from  its Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases from colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies, to be held at the Fira Barcelona October 29-31, 2025. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-

BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent

Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA ("Oncoinvent") regarding key dates for completion of the combination of the two companies through a statutory triangular merger (the "Merger"). Reference is further made to the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the "Prospectus") prepared in connection with the Merger and the contemplated rights issue in the combined company.The last day of trading in the shares of Oncoinvent on Euronext Growth Oslo

BerGenBio and Oncoinvent – Key Dates for Completion of Merger

Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio ASA (OSE: BGBIO) ("BerGenBio") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") regarding the combination of the two companies through a statutory triangular merger (the "Merger"), and the announcements on 4 August 2025 regarding the approval of the merger plan by the extraordinary general meetings of BerGenBio and Oncoinvent, respectively.It is currently expected that completion of the Merger will occur on 29 October 2025. Key dates and information for

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.

Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinical-stage radiopharmaceutical company, have entered into a strategic agreement for Thorium-228 radioisotopes to supply the Phase 3 clinical program for Radspherin®, Oncoinvent’s lead product candidate.Under the terms of the agreement, Thor Medical will supply Thorium-228 from AlphaOne, the company’s first commercial-scale manufacturing plant currently under construction. Thorium-228 from Thor Medical will serve as the starting material for the

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.Highlights for the first half of 2025: Radspherin® •             Positive final data from Phase1/2a trial in colorectal cancer patients •             Positive interim 18-months data from Phase1 trial in ovarian cancer patients •             Positive read-out of safety lead-in cohort and opening of randomized part of Phase 2 trial in ovarian cancer patients •             Regulatory approvals for additional sites for the

Oncoinvent shareholders approve the merger plan with BerGenBio

Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA ("Oncoinvent") and BerGenBio ASA ("BerGenBio") regarding the contemplated combination of the two companies through a statutory merger (the "Merger"). An extraordinary general meeting (the "EGM") in Oncoinvent was held today at 12:00 hours (Oslo time). All proposals on the agenda were approved with the requisite majority, including the merger plan for the Merger dated 30 June 2025 (the "Merger Plan").As separately announced by BerGenBio today, the merger and the

Oncoinvent ASA: Notice of Extraordinary General Meeting

An extraordinary general meeting in Oncoinvent ASA will be held on 4. August 2025 at  12:00 CEST. The meeting will be held in Gullhaugveien 7, Oslo with the possibility for a virtual participation. The formal call will be sent to all shareholders registered in the Norwegian Central Security Depository (VPS). The complete set of documents and link relating to the extraordinary general meeting will be made available on www.oncoinvent.com/investors/general-meetings. Shareholders are recommended to exercise their shareholder rights through completing the proxy form with voting instruction.

Announcement of fully underwritten rights issue

Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company’s existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately NOK 130 million, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Bergen, Norway and Oslo, Norway, 30 June 2025 – BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.Following the Merger, the combined company shall carry out a fully underwritten rights issue. · The Merger puts BerGenBio’s capital and listing to productive use by strengthening Oncoinvent’s ability to execute on its clinical strategy and advance

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancerOncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, is thrilled to announce positive topline data from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer. Reducing peritoneal recurrence in colorectal cancer is critically important because peritoneal metastases

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English on Wednesday 30[th] of April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up.In this trial, 10 patients received a single intraperitoneal dose of 7 MBq Radspherin®. Oncoinvent reported 12-month data in November  2024, where only 1 out of the 10

Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer.Radspherin® is a novel alpha-radiation therapy designed for targeted, direct treatment of cancers that have spread to body cavities. The Phase 2 is a randomised, open label, multicentre trial (NCT06504147) assessing the efficacy and safety of Radspherin® in patients with

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

Oslo, Norway 20, February 2025   In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:   Thursday 27 February 2025 07.30 CET Release of stock exchange notification. Press release, quarterly report and presentation will be available on www.oncoinvent.com.   10.00 CET Live streamed of quarterly presentation in English. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.   About Oncoinvent

Oncoinvent ASA announces oversubscribed private placement

Oncoinvent ASA ("Oncoinvent" or the "Company") is pleased to announce that it has today successfully completed the bookbuilding process for a private placement of new shares and that gross proceeds of NOK 130 million is being raised by the issuance of 65,000,000 new shares (the "Offer Shares") at a subscription price of NOK 2 per share (the "Private Placement").“We are pleased to announce the successful completion of the private placement with a contemplated subsequent listing on Euronext Growth Oslo. I would like to express my gratitude for shareholders' full support and trust in our

Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed for recruitment at the end of 2023, and patients are currently in long-term follow-up. The readout confirmed the previously published results on efficacy and adds further confidence in the ongoing randomized controlled Phase 2 clinical trial for Radspherin® in patients with ovarian cancer.In the first interim readout from the Phase 1

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. Radspherin® is a novel alpha-radiation therapy candidate designed for targeted, local treatment of cancers that have spread to body cavities. The Phase 2 trial is a randomized controlled study designed to assess progression-free survival (PFS) in primary advanced ovarian cancer patients treated with Radspherin® following complete

BioStock: Fast Track designation facilitates development of Oncoinvent’s Radspherin

The FDA has granted Fast Track to Oncoinvent for its radiopharmaceutical Radspherin as a treatment for peritoneal metastases originating from ovarian cancer. This designation will facilitate the candidate’s clinical development, with the next step being a phase IIb trial first in ovarian cancer patients, then in colorectal cancer patients.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/fast-track-designation-facilitates-development-of-oncoinvents-radspherin/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Oncoinvent strengthens board and cash position

Oncoinvent has appointed esteemed industry leaders to its Board of Directors, led by Gillies O’Bryan-Tear as Chairman. Furthermore, the company has completed a private placement round of NOK 71 million, which enables advancement to phase IIb with Radspherin. BioStock reached out to Gillies O’Bryan-Tear for a comment.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/oncoinvent-strengthens-board-and-cash-position/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Rss